Q-omics provides the consensus-scored ELMOD1 profile across patient tissues and cancer cell-line models. ELMOD1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, ELMOD1 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, ELMOD1 protein abundance shows 17,704 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight CESC, KIRC, and GBM as cancer lineages where ELMOD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ELMOD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ELMOD1 survival associations across molecular data types. ELMOD1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ELMOD1 RNA expression–survival associations across cancer types. High ELMOD1 expression shows unfavorable associations in CESC, UVM, STAD, LUSC and LIHC, but favorable associations in UCS. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for ELMOD1 RNA expression.
This table summarizes ELMOD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ELMOD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ELMOD1 shows lower tumor expression in KIRC, KIRP, UCEC, LUAD, LUSC and STAD. The KIRC box plot shows higher ELMOD1 RNA expression in normal versus tumor tissue (log2 FC = −0.704, t-test p < 0.001).
This table shows molecular features associated with ELMOD1 in patient tissues and cancer cell lines. In patient samples, ELMOD1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ELMOD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Lymphoma.
